<HashMap><database>biostudies-literature</database><scores/><additional><submitter>McCallum M</submitter><funding>NIAID NIH HHS</funding><funding>Wellcome Trust</funding><funding>NIGMS NIH HHS</funding><funding>NIH HHS</funding><pagination>864-868</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9427005</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>375(6583)</volume><pubmed_abstract>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern evades antibody-mediated immunity that comes from vaccination or infection with earlier variants due to accumulation of numerous spike mutations. To understand the Omicron antigenic shift, we determined cryo-electron microscopy and x-ray crystal structures of the spike protein and the receptor-binding domain bound to the broadly neutralizing sarbecovirus monoclonal antibody (mAb) S309 (the parent mAb of sotrovimab) and to the human ACE2 receptor. We provide a blueprint for understanding the marked reduction of binding of other therapeutic mAbs that leads to dampened neutralizing activity. Remodeling of interactions between the Omicron receptor-binding domain and human ACE2 likely explains the enhanced affinity for the host receptor relative to the ancestral virus.</pubmed_abstract><journal>Science (New York, N.Y.)</journal><pubmed_title>Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.</pubmed_title><pmcid>PMC9427005</pmcid><funding_grant_id>S10 OD023476</funding_grant_id><funding_grant_id>DP1 AI158186</funding_grant_id><funding_grant_id>HHSN272201700059C</funding_grant_id><funding_grant_id>T32 GM008268</funding_grant_id><funding_grant_id>P30 GM124169</funding_grant_id><funding_grant_id>R01 GM120553</funding_grant_id><funding_grant_id>209407/Z/17/Z</funding_grant_id><pubmed_authors>Veesler D</pubmed_authors><pubmed_authors>Rosen LE</pubmed_authors><pubmed_authors>Joshi A</pubmed_authors><pubmed_authors>Walls AC</pubmed_authors><pubmed_authors>Dillen JR</pubmed_authors><pubmed_authors>Snell G</pubmed_authors><pubmed_authors>Powell AE</pubmed_authors><pubmed_authors>Hauser K</pubmed_authors><pubmed_authors>McCallum M</pubmed_authors><pubmed_authors>Czudnochowski N</pubmed_authors><pubmed_authors>Croll TI</pubmed_authors><pubmed_authors>Corti D</pubmed_authors><pubmed_authors>Stewart C</pubmed_authors><pubmed_authors>Bowen JE</pubmed_authors><pubmed_authors>Nix J</pubmed_authors><pubmed_authors>Zepeda SK</pubmed_authors><pubmed_authors>Virgin HW</pubmed_authors></additional><is_claimable>false</is_claimable><name>Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.</name><description>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern evades antibody-mediated immunity that comes from vaccination or infection with earlier variants due to accumulation of numerous spike mutations. To understand the Omicron antigenic shift, we determined cryo-electron microscopy and x-ray crystal structures of the spike protein and the receptor-binding domain bound to the broadly neutralizing sarbecovirus monoclonal antibody (mAb) S309 (the parent mAb of sotrovimab) and to the human ACE2 receptor. We provide a blueprint for understanding the marked reduction of binding of other therapeutic mAbs that leads to dampened neutralizing activity. Remodeling of interactions between the Omicron receptor-binding domain and human ACE2 likely explains the enhanced affinity for the host receptor relative to the ancestral virus.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2026-05-27T23:24:06.959Z</modification><creation>2026-04-08T01:59:39.217Z</creation></dates><accession>S-EPMC9427005</accession><cross_references><pubmed>35076256</pubmed><doi>10.1126/science.abn8652</doi></cross_references></HashMap>